Press release
Global Oncology Drugs Market - Competitive Analysis
Major manufacturers in the oncology drugs market include:
Roche
Celgene
Johnson & Johnson
Pfizer
Sanofi
Bristol-Meyers Squibb
Novartis
GlaxoSmithKline
Eli Lily
Merck & Co.
Get The Holistic SAMPLE With Research Methodology:
https://www.coherentmarketinsights.com/insight/request-sample/1437
Top 5 company described for competitive analysis in detail:
Roche is a world leader in oncology, which is engaged in developing new approaches for advanced cancer treatment. Roche operates in two segments, which includes pharmaceuticals and diagnostics with annual sales of US$ 39.1 Bn and US$ 11.5 Bn respectively. Roche is at the forefront of cancer immunotherapy with ten investigational drug candidates currently in the clinical development phase. In 2016, the company entered into 10 new clinical collaboration agreements to explore drug combinations for maximizing therapeutic benefits and develop the lead immunotherapy drug. The company has set up imCORE, a network of 21 academic institutions working with Roche to advance research into cancer immunotherapies, thus contributing to enhance the global oncology drugs market in the near future.
Johnson and Johnson operates in three business segments namely consumer, pharmaceutical and medical devices. The business of Johnson & Johnson is conducted by more than 230 operating companies located in 60 countries worldwide. In 2016, the company has invested around US$ 9.1 Bn in research and development activities. Janssen, the pharmaceutical division of J&J registered the oncology drug sales of around US$ 5.9 Bn among the total pharmaceutical therapeutic area sales. Janssen is focused on strategic collaborations for the development of cancer therapeutics, which in turn favors the oncology drugs market. For instance, in November, 2017, Janssen collaborated with Zymeworks, Inc. to develop six bispecific antibodies based on Azymetric and Effector Function Enhancement and Control Technology (EFECT) platforms for research, development, and commercialization with a potential to generate US$ 1.5 Bn. High sales of IMBRUVICA (ibrutinib) and DARZALEX (daratumumab) were due to increasing patient uptake, additional country launches, and additional indications, which contributed to the growth of oncology drugs.
Pfizer, Inc. develops oncology therapies that provide maximum efficacy while minimizing adverse effects on the patient. The current portfolio of oncology drugs covers a range of cancers. The company studies these therapies alone and in combination with other treatments to improve the lives of cancer patients. Pfizer’s overall strategy is anchored on innovation for developing new medicines and vaccines through collaborations and business relationships which is expected to bolster the oncology drugs market. For instance, Pfizer partnered with Merck KGaA for building a strong portfolio in immuno-oncology, Biolnvent International AB to develop antibodies to advance the novel technology platform of cancer vaccine as well as business relationship with IBM Watson for drug discovery by identifying potential new targets and combination therapies in immune-oncology.
Novartis’s aims to develop approaches for extending the lives of people suffering from cancer, by adopting the strategy to use science-based innovation for delivering better patient outcomes in growing areas of healthcare. Novartis operates in two business segments namely Novartis Oncology and Novartis Pharmaceuticals, which together form Innovative Medicines Division. The Novartis Oncology segment contributed around 39% of its net sales, it was valued around US$ 12.8 Bn. Increase in revenue is attributed to the strong performance for oncology products Tafinlar + Mekinist, a combination therapy for advanced melanoma, and Jakavi, for blood cancers. Novartis is leading provider of cancer treatments, following the acquisition of oncology products from GlaxoSmithKline in 2015. In 2016, the company collaborated with Surface Oncology to bolster the cancer immunotherapy pipeline that will provide access to four preclinical programs. Also, with a licensing agreement with Xencor, it plans to co-develop two bispecific antibodies designed to target acute myeloid leukemia and B-cell malignancies, thereby aiding the growth of oncology drugs market.
Get Table Of Content:
https://www.coherentmarketinsights.com/ongoing-insight/toc/1437
Sanofi operates through two business segments namely pharmaceuticals and vaccines. Sanofi gains insights through its network of collaborations with biotech companies such as Immunogen and Evotec, academic cancer centers such as Institut Gustave Roussy, Institut Curie, and the Dana Farber Cancer Institute, enabling superior use of software, analytics, and new technology, which helps to increase its productivity, maximize return on R&D investment, and accelerate the development of new products. Sanofi Oncology has a large number of collaborations and alliances to support its R&D portfolio. In 2015, Sanofi collaborated with Regeneron focusing on cancer immunotherapy to generate high value development candidates in the emerging field of immuno-oncology and to accelerate its development pipeline in the oncology drugs market. In 2016, the company entered into a collaboration with Innate Pharma to develop innovative bispecific antibody formats engaging natural killer (NK) cells to kill tumor cells. Also, it collaborated with Warp Drive Bio to develop drugs targeting human oncogenes, thus accelerating the innovations for oncology drugs.
Novel and targeted oncology drugs manufactured by the major competitors in oncology drug market are geared towards the treatment of specific type of cancer with premium prices, without generic competition from the competitors, as these biologic treatments have an enhanced patent protection. Strategic collaborations and rise in research and development is the basic approach adopted by the manufacturers, as it helps to develop and access knowledge and increase the understanding in new areas of science, thereby accelerating the global oncology drugs market.
The major strategic collaborations included in the competitive analysis include:
Sanofi and Regeneron collaborated to develop REGN2810, with an overall expenditure of US$ 325 million each towards developing the therapy currently in the Phase I
Bristol-Myers Squibb (BMS) and CytomX Therapeutics collaborated to develop four target cancer therapies using CytomX’s Probody drug discovery platform. The collaboration would provide CytomX with a net US$ 1.2 Bn.
Buy This Exclusive Report:
https://www.coherentmarketinsights.com/insight/buy-now/1437
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Oncology Drugs Market - Competitive Analysis here
News-ID: 1011410 • Views: …
More Releases from Pharmaceutical Report
Batten Disease Treatment Market - Global Industry Insights, Trends, Outlook, and …
Batten disease is a rare, inherent, and fatal autosomal recessive neural disorder that begins in the childhood but may take a few years to show symptoms. Batten disease is one of the approximately 50 diseases that fall under the category of lysosome shortage disorders. The batten disease also referred as Neuronal ceroid Lipofuscinoses (NCLs), which is a class of life-limiting genetic neurogenerative diseases that are caused due to abnormality of…
Opioids – Reducing body pain but increasing pain for regulatory authorities
Opioids are drugs primarily prescribed for pain management and treatment of diarrhea and cough. Opioid drugs are of two types namely, agonist and antagonist. Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone, Diphenoxylate, Hydromorphone, Methylphenidate, Oxycodone, and Oxymorphone are classified as agonists, while Buprenorphine, Naloxone, Naltrexone, Methylnaltrexone, and Nalbuphine are classified as antagonists. Due to easy availability of opioids, these drugs are rampantly overused globally and the situation is more critical in…
Human Chorionic Gonadotropin (HCG) Market to Rear Excessive Growth During 2016 â …
Human chorionic gonadotropin hormone (HCG) is a hormone secreted by the placenta after implantation of a fertilized zygote in the uterus. The hormone also supports normal development of an egg and helps in the stimulation of egg release from the ovary. The HCG is mainly used to induce ovulation in the women under infertility treatment. It is also used among males mostly to increase the sperm count and in young…
Medical Waste Management Market, By Services, and By Techniques - Global Industr …
Healthcare activities generates a lot of waste, especially from the frequently used consumables, which are harmful for in-patients and healthy population. Medical waste includes waste generated within research centers and health-care facilities for example, sharps waste, infectious waste, pathological waste, pharmaceutical waste, chemical waste, and radioactive waste. The waste product that are generated by the healthcare activities have higher potential to spread infection and injuries. Inadequate or incorrect handling of…
More Releases for Novartis
Oncology Drugs Market Competitive Outlook - GlaxoSmithKline, Novartis, Merck
"The oncology drugs market consists of sales of oncology drugs and related services by entities (organizations, sole traders and partnerships) that produce oncology drugs to diagnose and treat all types of cancers. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain tumor, and other cancer types. The pharmaceutical industry develops drugs to…
Rydapt Market 2020 Clinical Analysis – Novartis
Global Rydapt Market Growth 2020-2025
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Rydapt Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought…
Gleevec Market Overall Study Report 2020-2027 | Novartis
Gleevec Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Gleevec market between 2020 and 2027. In terms of value, the Gleevec industry is expected to register a steady CAGR during the forecast period.
The report offers a systematic presentation of the existing trends,…
Rydapt Market Demand & Competitive Analysis by 2025| Novartis
Market Research Report Store offers a latest published report on Rydapt Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth…
Global HER2-negative breast cancer Treatment Market to 2025| AstraZeneca, Bristo …
Researchmoz added Most up-to-date research on "Global HER2-negative breast cancer Treatment Market Size, Status and Forecast 2019-2025" to its huge collection of research reports.
HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein.
In 2018, the global HER2-negative breast cancer Treatment…
Nilotinib Market Report 2018 – 2023: Novartis
The Study Paper in this Global Nilotinib Market includes Novartis.
Get Free Sample Brochure of Nilotinib Market spread across [142 pages] @ https://www.marketgrowthinsight.com/sample/4896
Unbiased perspective on intangible aspects such as key challenges, threats, new entrants as well as strengths and weaknesses of the prominent vendors too are…
